News & Updates

Levonorgestrel-releasing intrauterine system linked to increased breast cancer risk

23 Mar 2025

Exposure to the levonorgestrel-releasing intrauterine system, especially during the first few years, appears to contribute to a heightened risk of breast cancer among women with abnormal uterine bleeding, endometriosis, or leiomyomas, according to a retrospective study.

Levonorgestrel-releasing intrauterine system linked to increased breast cancer risk

23 Mar 2025

First HIV cure trial affirms tolerability of investigational combo in women with HIV

21 Mar 2025 by

A phase IIa study affirms the tolerable safety of a combination regimen comprising three investigational compounds – two broadly neutralizing antibodies (bNAbs), VRC07-523LS and CAP256V2LS, and the TLR7 agonist vesatolimod – in women with HIV-1.

First HIV cure trial affirms tolerability of investigational combo in women with HIV

21 Mar 2025

Menstrual characteristics in reproductive years may provide clue to lung health in middle age

17 Mar 2025

Report of heavy menstrual bleeding, severe period pain, and premenstrual syndrome during women’s reproductive years is linked to increased odds of having asthma in middle age, according to a study. On the other hand, irregular period is only associated with asthma when reported during women’s 40s.

Menstrual characteristics in reproductive years may provide clue to lung health in middle age

17 Mar 2025

Abnormal uterine bleeding during menopause transition linked to fatigue

15 Mar 2025

Women experiencing heavy or prolonged menstrual bleeding during the menopause transition appear to be predisposed to fatigue, according to a study.

Abnormal uterine bleeding during menopause transition linked to fatigue

15 Mar 2025

Original New Drug Application Approvals by US FDA (16-28 February 2025)

14 Mar 2025

New drug applications approved by US FDA as of 16-28 February 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-28 February 2025)

14 Mar 2025

Young adults unaware of male HPV infection, vaccine benefits

13 Mar 2025 by

Awareness about human papillomavirus (HPV) infection in males and the benefits of vaccination on both genders is low among young adults, reveals a Singapore study.

Young adults unaware of male HPV infection, vaccine benefits

13 Mar 2025

Drospirenone safer than levonorgestrel when co-administered with psychotropics

12 Mar 2025

For women using contraceptives while on psychotropic drugs, the risk of adverse events appears to be lower with drospirenone than with levonorgestrel, whereas contraceptive failure is uncommon across progestins, according to a real-world study.

Drospirenone safer than levonorgestrel when co-administered with psychotropics

12 Mar 2025

Mobile app tracks BP changes in pregnant women

11 Mar 2025 by

Blood pressure (BP) estimates in pregnant women of the mobile app OptiBP meet the AAMI/ESH/ISO 81060-2:2018 criteria and are on a par with that of an oscillometric device, reports a study.

Mobile app tracks BP changes in pregnant women

11 Mar 2025

Original New Drug Application Approvals by US FDA (1-15 February 2025)

10 Mar 2025

New drug applications approved by US FDA as of 1-15 February 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 February 2025)

10 Mar 2025

Sustained PFS benefit in breast cancer with palbociclib + exemestane with ovarian function suppression

09 Mar 2025

Treatment with palbociclib plus exemestane with ovarian function suppression does not appear to produce improvements in overall survival (OS), although it yields sustained increases in progression-free survival (PFS) as compared with capecitabine in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer, according to updated data from the phase II Young-PEARL study.

Sustained PFS benefit in breast cancer with palbociclib + exemestane with ovarian function suppression

09 Mar 2025

News & Updates

Filter by Specialty:

Specialty:

Levonorgestrel-releasing intrauterine system linked to increased breast cancer risk

Levonorgestrel-releasing intrauterine system linked to increased breast cancer risk

First HIV cure trial affirms tolerability of investigational combo in women with HIV

First HIV cure trial affirms tolerability of investigational combo in women with HIV

Menstrual characteristics in reproductive years may provide clue to lung health in middle age

Menstrual characteristics in reproductive years may provide clue to lung health in middle age

Abnormal uterine bleeding during menopause transition linked to fatigue

Abnormal uterine bleeding during menopause transition linked to fatigue

Original New Drug Application Approvals by US FDA (16-28 February 2025)

Original New Drug Application Approvals by US FDA (16-28 February 2025)

Young adults unaware of male HPV infection, vaccine benefits

Young adults unaware of male HPV infection, vaccine benefits

Drospirenone safer than levonorgestrel when co-administered with psychotropics

Drospirenone safer than levonorgestrel when co-administered with psychotropics

Mobile app tracks BP changes in pregnant women

Mobile app tracks BP changes in pregnant women

Original New Drug Application Approvals by US FDA (1-15 February 2025)

Original New Drug Application Approvals by US FDA (1-15 February 2025)

Sustained PFS benefit in breast cancer with palbociclib + exemestane with ovarian function suppression

Sustained PFS benefit in breast cancer with palbociclib + exemestane with ovarian function suppression